Line Seguy
Caen, 14000, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Enhancing brain delivery of tegaserod for Alzheimer's disease: a pharmaceutical comparison of two nanocarrier-based strategies.
Journal: International journal of pharmaceutics
Published: April 03, 2026
Evidence from a mouse model supports repurposing an anti-asthmatic drug, bambuterol, against Alzheimer's disease by administration through an intranasal route.
Journal: Communications biology
Published: January 03, 2024
In vitro evaluation of NA1-115-7-loaded nanoemulsions, an MCL-1-specific inhibitor of natural origin, intended to treat B-cell lymphoproliferative disorders after oral administration.
Journal: International journal of pharmaceutics
Published: July 18, 2022
NA1-115-7, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: June 16, 2022
How nano-engineered delivery systems can help marketed and repurposed drugs in Alzheimer's disease treatment?
Journal: Drug discovery today
Published: September 30, 2021
Active Targeted Nanoemulsions for Repurposing of Tegaserod in Alzheimer's Disease Treatment.
Journal: Pharmaceutics
Published: September 10, 2021
Drimane Derivatives as the First Examples of Covalent BH3 Mimetics that Target MCL-1.
Journal: ChemMedChem
Published: January 07, 2021
Design of Non-Haemolytic Nanoemulsions for Intravenous Administration of Hydrophobic APIs.
Journal: Pharmaceutics
Published: October 15, 2020
8-Alkynyl-3-nitroimidazopyridines display potent antitrypanosomal activity against both T. b. brucei and cruzi.
Journal: European journal of medicinal chemistry
Published: March 17, 2020
Showing 1-9 of 9
Last Updated: 09/26/2026